Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
详细信息 查看全文
- 作者：Mohamed Shanavas1 ; Uday Popat2 ; Laura C. Michaelis3 ; Veena Fauble4 ; Donal McLornan5 ; Rebecca Klisovic6 ; John Mascarenhas7 ; Roni Tamari8 ; Murat O. Arcasoy9 ; James Davies10 ; Usama Gergis11 ; Oluchi C. Ukaegbu12 ; Rammurti T. Kamble13 ; John M. Storring14 ; Navneet S. Majhail15 ; Rizwan Romee16 ; Srdan Verstovsek17 ; Antonio Pagliuca5 ; Sumithira Vasu6 ; Brenda Ernst4 ; Eshetu G. Atenafu18 ; Ahmad Hanif3 ; Richard Champlin2 ; Paremeswaran Hari3 ; Vikas Gupta1 ; vikas.gupta@uhn.ca" class="auth_mail" title="E-mail the corresponding author
- 关键词：JAK1/2 inhibitors ; Ruxolitinib ; Myelofibrosis ; Allogeneic transplantation ; Survival
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：22
- 期：3
- 页码：432-440
- 全文大小：710 K
文摘
- •
Use of Janus kinase 1/2 inhibitors before hematopoietic cell transplantation had no adverse impact on early outcomes.
- •
Continuation of Janus kinase 1/2 inhibitors closer to start of conditioning is recommended.
- •
Patients undergoing hematopoietic cell transplantation when responding to Janus kinase 1/2 inhibitors had encouraging outcomes.